iCardio.ai accepted to Jerusalem venture partner's #PlayBeyondBio program.

iCardio.ai
iCardio.ai
iCardio.ai is a Los Angeles-based company that develops machine learning and deep learning algorithms for the analysis of ultrasound applications, with a specific focus on transthoracic echo. Leveraging a database of over +200M images, iCardio.ai is bringing AI to echocardiography.

"The world has changed and with it the world health systems. Today we face significant challenges. Only by combining our powers can we overcome them. We did it once, and now we're off for the second round!

Using AI to monitor the development of cancer cells? A bracelet to monitor lung diseases? Deciphering echocardiography by innovative means? This may sound like the opening of a science fiction movie. No. These are start-ups that deal with the issues that concern each and every one of us. The future lies in digital health.

Yesterday we launched, for the second time, the #PlayBeyondBio program for #Digital#Health startups, backed by a combination of leading international partners: AstraZeneca, Accenture Israel, Amazon Web Services (AWS), and the Shaare Zedek Medical Center, Jerusalem, and Margalit Startup City.

This year, our focus is on companies that develop tools that know how to predict and diagnose the diseases that our health systems will face. We are excited to be a significant part of this extraordinary collaboration - which can save lives.

We would like to thank all our partners and all the companies that have applied to participate in the program.

Thank you and good luck to all!

Jerusalem Venture Partners

About PlayBeyondBio

PlayBeyondBio is a 6 months program created for digital health companies that are building innovative products. The program is looking for innovators in the following therapeutic fields: oncology and hemato-oncology, respiratory, cardiovascular, and renal and metabolic diseases

Companies accepted are awarded fast-track assistance, focusing on commercialization agreements, implementation, and investments from the program's partners: JVP Fund, global pharma giant AstraZeneca, international consulting firm Accenture, Margalit Startup City community, AWS, and the Shaare Zedek Medical Center.

The program offers its participants the opportunity to leverage AstraZeneca’s expertise in the realms of science, regulation, medical and go-to-market; to work with experts on proof of concept development and testing it within the program's partners’ network of healthcare systems, government bodies, tech companies, academia and others; receive JVP’s support on roadmap, venture building and business strategy, with the potential to obtain funding from JVP and partners down the road and more.

About Jerusalem Venture Partners (JVP)

Jerusalem Venture Partners (JVP) is an internationally recognized venture capital fund with offices in Jerusalem, Israel, and in New York City, US.

Established in 1993 by Dr. Erel Margalit, JVP has raised over $1.4 billion and is ranked by Preqin as one of the top-ten consistently performing VC firms worldwide. Over the years, JVP has built over 140 companies in Israel, US, Europe, Asia and continues to leverage its market expertise, as well as a substantial capital base to build companies that disrupt global markets.

JVP has also partnered with the City of New York to launch the International Cyber Center in the heart of SoHo, NYC. JVP partnered with NYCEDC, the city’s leading academic institutions and with Fortune 500 corporations to provide start-up companies with strategic guidance, business development, and company building resources.

With a view of building category leaders, JVP invests in early through growth-stage companies in the spaces of Cybersecurity, Big Data, Fintech, Foodtech, Agtech, Digital Health, Enterprise Software, Storage, Mobile, Media, and IoT.

As a pioneering firm in the Israeli venture capital industry, JVP has contributed significantly to multiple successful portfolio company exits through industry sales and NASDAQ IPO's. To date, JVP has helped orchestrate 35 prominent portfolio companies exits, 12 of which are Initial Public Offerings on NASDAQ. In 2014, JVP concluded the IPO of Cyber-Ark Software (NASDAQ: CYBER), Israel's then most prominent private cyber company.

Over the years JVP has forged deep strategic partnerships with global corporations working together to identify and build some of the largest and leading companies emerge from Israel today. In recent years JVP has also integrated these partners into the funds, creating a closer collaboration between the fund, its partners, its portfolio and these major global players.

About iCardio.ai

iCardio.ai is a Los Angeles-based company that develops machine learning and deep learning algorithms for the analysis of ultrasound applications, with a specific focus on transthoracic echo. Leveraging a database of over +200M images, iCardio.ai is bringing AI to echocardiography.
See our demo